**Pseudomonas aeruginosa** Exploits Lipid A and Muropeptides Modification as a Strategy to Lower Innate Immunity during Cystic Fibrosis Lung Infection

Cristina Cigana1*, Laura Curcurù2*, Maria Rosaria Leone3*, Teresa Ierano3, Nicola Ivan Lorè1, Irene Bianconi1, Alba Silipo3, Flora Cozzolino3, Rosa Lanzetta3, Antonio Molinaro3, Maria Lina Bernardini2,4, Alessandra Bragonzi1*

1 Infection and Cystic Fibrosis Unit, San Raffaele Scientific Institute, Milano, Italy, 2 Dipartimento di Biologia Cellulare e dello Sviluppo, Sapienza-Università di Roma, Roma, Italy, 3 Dipartimento di Chimica Organica e Biochimica, Università di Napoli Federico II, Napoli, Italy; 4 Istituto Pasteur-Fondazione Cenci Bolognetti, Roma, Italy

**Abstract**

*Pseudomonas aeruginosa* can establish life-long airways chronic infection in patients with cystic fibrosis (CF) with pathogenic variants distinguished from initially acquired strain. Here, we analysed chemical and biological activity of *P. aeruginosa* Pathogen-Associated Molecular Patterns (PAMPs) in clonal strains, including mucoid and non-mucoid phenotypes, isolated during a period of up to 7.5 years from a CF patient. Chemical structure by MS spectrometry defined lipopolysaccharide (LPS) lipid A and peptidoglycan (PGN) muropeptides with specific structural modifications temporally associated with CF lung infection. Gene sequence analysis revealed novel mutation in *pagI*, which supported lipid A changes. Both LPS and PGN had different potencies when activating host innate immunity via binding TLR4 and Nod1. Significantly higher NF-kB activation, IL-8 expression and production were detected in HEK293hTLR4/MD2-CD14 and HEK293hNod1 after stimulation with LPS and PGN respectively, purified from early *P. aeruginosa* strain as compared to late strains. Similar results were obtained in macrophages-like cells THP-1, epithelial cells of CF origin IB3-1 and their isogenic cells C38, corrected by insertion of cystic fibrosis transmembrane conductance regulator (CFTR). In murine model, altered LPS structure of *P. aeruginosa* late strains induces lower leukocyte recruitment in bronchoalveolar lavage and MIP-2, KC and IL-1β cytokine levels in lung homogenates when compared with early strain. Histopathological analysis of lung tissue sections confirmed differences between LPS from early and late *P. aeruginosa*. Finally, in this study for the first time we unveil how *P. aeruginosa* has evolved the capacity to evade immune system detection, thus promoting survival and establishing favourable conditions for chronic persistence. Our findings provide relevant information with respect to chronic infections in CF.

**Citation:** Cigana C, Curcurù L, Leone MR, Ierano T, Lorè NI, et al. (2009) *Pseudomonas aeruginosa* Exploits Lipid A and Muropeptides Modification as a Strategy to Lower Innate Immunity during Cystic Fibrosis Lung Infection. PLoS ONE 4(12): e8439. doi:10.1371/journal.pone.0008439

**Copyright:** © 2009 Cigana et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported to AM and MLB by Fondazione per la ricerca sulla Fibrosi Cistica (FFC 2007) with the contribute of Furla Spa, Grazia Valentini Scaglairini Spa, Delegazione FFC di Bologna and to AB by HEALTH-F7-2009-223670. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: *bragonzi.alessandra@hsr.it

# These authors contributed equally to this work.

**Introduction**

The strategy of innate immune recognition is based on the detection of constitutive and conserved products of microbial metabolism called pathogen-associated molecular patterns (PAMPs) or alternatively microbe-associated molecular patterns (MAMPs), since they are also common to all microbe and not only to the pathogen version [1]. These molecular signatures are recognized by the host through a family of pattern recognition receptors (PRRs), which includes Toll-like (TLRs) and nucleotide binding and oligomerization domain-like receptors NLR (Nod-Like receptor) [2]. For example, lipid A contained in bacterial lipopolysaccharide (LPS) acts as a PAMP and is sensed by the cognate PRR TLR4-MD2, while different motifs contained in peptidoglycan (PGN) of Gram-positive or Gram-negative bacteria are recognized by the intracellular PRRs Nod1 and Nod2 [3,4]. Interaction of PAMPs with PRRs results in activation of antimicrobial responses [1], such as production of antimicrobial peptides and secretion of pro-inflammatory cytokines, necessary for pathogen’s eradication. However, many pathogens have evolved adaptive strategies for subverting the host innate immune system by evading detection by PRRs and/or impairing the downstream cellular signalling pathway [5]. In this study, we present evidence that *Pseudomonas aeruginosa* exploits PAMPs modification as a strategy to lower innate immune system detection and signalling during chronic stages of lung infection in fibrosis cystic (CF) patients.

CF lung disease is characterized by transient airway *P. aeruginosa* infections and excessive neutrophil-dominated inflammation early in life followed by permanent chronic infection that causes persistent respiratory symptoms and decline in lung functions [6]. The long term colonization of CF airways selects pathoadaptive variants with several features which differentiate late *P. aeruginosa*
isolates from the initially acquired strain [7,8]. *P. aeruginosa* strains that initiate infections are characterized by a large arsenal of virulence factors, such as many toxic factors, like pyocyanin, a type III secretion system (T3SS), several proteases, lipases and phospholipases, rhamnolipids and other factors [9]. In contrast, these invasive functions are selected against in CF chronic infection leading to less virulent but more persistent phenotypes including alginate producing mucoid strains [7]. However, besides all these relevant features, which contribute to either forms of infection, the LPS modification appears to be one of the main factors in the adaptation of this pathogen during chronic infections. It is already known that *P. aeruginosa* acute infection also implies a consistent change in LPS lipid A structure [10] even though no conclusive information are present on the putative LPS lipid A changes in the acute to chronic evolution of the infection. In general, production of fully hexa-acylated lipid A is associated with a more strong TLR4 mediated inflammatory response while lipid A with lower levels of acylation triggers reduced cellular responses [11]. However, lipid A isolated from clinical strains of *P. aeruginosa* often results in a blend of different species [10] with a resulting biological activity that might be different when compared to single species bioactivity. Lipid A modifications are regulated by the environmental sensor-kinase transcriptional regulatory system PhoP-PhoQ and catalysed by PagP, PagL, and LpxO which lead to acylation, deacetylation and hydroxylation of the molecule, respectively [12,13,14].

As for PGN, an essential cell wall component, no data have been produced so far on the structure itself and eventual alterations in infection by *P. aeruginosa*. PGN changes may even more advantage bacterial life within the host and contribute to establish successful chronic infection in CF patients. In fact, in these last years a growing body of studies are highlighting the role played by muropeptide receptors Nod1 and Nod2 in the development of both antibacterial responses and chronic inflammation, such as Crohn’s disease and asthma [15]. To fill the gap in the context of CF disease mediated by *P. aeruginosa* infection we analysed, at chemical and biological level, the LPS and PGN from three clonal strains of one *P. aeruginosa* lineage. *P. aeruginosa* strains were isolated at the onset of infection and after years of chronic colonization from a CF patient with a severe course of the airways infection [8]. Our results showed that the biological activity of LPS and PGN is consistent with a reduced immunostimulatory potential in accordance with the need to evade immune system and favour survival during the course of the chronic *P. aeruginosa* infection.

**Results**

*P. aeruginosa* Lipid A Chemical and Genetic Modifications in Clonal Strains of Early Colonization and Late Chronic Infection of CF Patient

The LPS of *P. aeruginosa* sequential strains AA2, isolated at the onset of chronic colonization, and AA43 (mucoid) and AA44, isolated before patient’s death (Figure S1), was extracted by conventional methods (see Supporting Information File S1) and showed the typical ladder like pattern by SDS-PAGE electrophoresis (data not shown). The O-repeating unit resulted identical in all three strains and the structure is already reported elsewhere [16]. The structure of LPS lipid A of the three *P. aeruginosa* strains (Figure 1) was determined by chemical analyses and MS spectrometry (see Supporting Information File S1 for the whole structure determination). As shown in Figure 1, MALDI negative ion spectra revealed that LPSs extracted from AA2 and AA43 presented the same lipid A species even though with a different relative abundance. In both cases, MALDI mass spectra showed a main peak that matched with a penta-acylated lipid A constituted by a bi-phosphorylated disaccharide backbone carrying a 10:0 (3-OH) in ester linkage on GlcN II and two 12:0 (3-OH) in amide linkage on both GlcN residues. Furthermore, both 12:0 (3-OH) were substituted by a secondary fatty acid, a 12:0 on GlcN II and a 12:0 (2-OH) on the GlcN I. Both lipid A blend also contained a tetra-acylated lipid A deriving from the previous by loss of the only 10:0 (3-OH) in ester linkage on GlcN II. An asymmetric hexa-acylated lipid A bearing the extra 16:0 that esterifies the 10:0 (3-OH) on GlcN II was present almost exclusively in the lipid A blend of strain AA43. Minor species carrying two secondary 12:0 (2-OH) fatty acids and others lacking a phosphate group were also present.

As for AA44 completely different lipid A were found, in which the main difference with those above was the presence of a further 10:0 (3-OH) on GlcN I. The most prevalent one was a symmetric hexa-acylated lipid A constituted by a bi-phosphorylated disaccharide backbone carrying two 10:0 (3-OH) in ester linkage and two 12:0 (3-OH) in amide linkage. Further, both amide chains were substituted by a secondary fatty acid, a 12:0 and a 12:0 (2-OH) on the GlcN II and I, respectively. In addition, hepta-acylated lipid A bearing the additional 16:0 on GlcN II species was present.

Lipid A modifications in AA2, AA43 and AA44 were stable as they were not lost after serial passages in vitro, which would suggest the presence of genetic mutations. Sequence analysis and multiple alignment of *phoP*, *phoQ*, *pagL*, *lpxO1* and *lpxO2* genes responsible for modifying lipid A, revealed *pagL* mutation in AA44 but not in AA2 and AA43 strains (Table S1 in Supporting Information File S1 and Figure S2). In particular, insertion of four nucleotides (CCTG) at position 502 lead to a frameshift mutation.

**LPS of *P. aeruginosa* Clinical Isolates Stimulates Different Inflammatory Response in Human Cells (HEK 293-hTLR4/MD-2-CD14, C38 and THP-1) Including Those of CF Origin (IB3-1)**

HEK 293-hTLR4/MD-2-CD14, C38 and THP-1 were exposed to different LPSs concentration (10, 50 and 100 ng/mL) of *P. aeruginosa* AA2, AA43, AA44 and PAO1 for 4 h and NF-kB activation was evaluated through the assessment of luciferase activity (Figure 2A). LPS of *P. aeruginosa* AA2 induced a significantly higher NF-kB activation with respect to cells exposed to LPSs of AA43 and AA44 (LPS AA2 vs AA43 and AA44 p<0.01) in a dose dependent manner. IL-8 expression was measured through real time quantitative q-PCR after 4 h stimulation, as above (Figure 2B). In accordance with NF-kB activity, the level of IL-8 expression increased higher after stimulation with LPS from AA2 with respect to LPSs from AA43 and AA44 (LPS AA2 vs AA43 and AA44 p<0.01). For ELISA assay, HEK 293-hTLR4/MD-2-CD14 were stimulated for 24 h with *P. aeruginosa* LPS as above (Figure 2C). The level of IL-8 release induced by LPS from AA2 was significantly higher than that induced by LPSs of AA43 and AA44 (LPS AA2 vs AA43 and AA44 p<0.05). Under all conditions, stimulation with LPS from PAO1 was considerably higher than those induced by LPSs from the clinical isolates (LPS PAO1 vs AA2, AA43 and AA44 p<0.05) (Figure 2A, B and C).

Next, we tested CF respiratory cells (IB3-1) and the isogenic corrected cells (C38) after LPS stimulation. When tested for the pro-inflammatory markers, in IB3-1 cells LPS from AA2 induced significantly more IL-8 and TNF-α expression, assessed by real time q-PCR, when compared with LPSs from AA44 and AA43 (LPS AA2 vs AA43 and AA44 p<0.05) (Figure 3A and C). IL-8 protein release, measured by ELISA, was consistent with expression (LPS AA2 vs AA43 and AA44 p<0.05) (Figure 3B). Similar results were
Figure 1. Chemical structure of *P. aeruginosa* lipid A. MALDI MS spectra of lipid A blend obtained by acid hydrolysis of LPS from *P. aeruginosa* clinical strains isolated at the onset of chronic colonization (AA2) (A) and after years of chronic infection (AA43 and AA44) from a CF patient (B and C). A difference of 238 Da corresponds to a 16:0 fatty acid residue whereas 170 corresponds to a 10:0 (3-OH) residue and 80 Da are indicative of a phosphate group. The 16 Da difference is relative to the presence of a Hydroxy group at C-2 of the secondary 12:0 fatty acids. The non indicated ion peaks are relative to the species already indicated and bearing sodium or potassium counter-ions.

doi:10.1371/journal.pone.0008439.g001
obtained in C38 cells, even though these cells were generally less responsive when compared to IB3-1. LPS from PAO1 was used as positive control and stimulated both IB3-1 and C38 cells (Figure 3A, B and C).

As levels of TNF-α secretion were undetectable in epithelial cell lines, we evaluated LPS stimulation in differentiated macrophagic THP-1 cells (Figure 3D). TNF-α protein release was significantly higher after treatment with LPS from AA2 in comparison to that induced by LPSs from AA43 and AA44 (LPS AA2 vs AA43 and AA44 p < 0.05). LPSs from PAO1 and E. coli OIII:B4 were used as positive controls and both stimulated THP-1 cells.

Altered LPS Structure of P. aeruginosa Late Strains Induces Low Leukocyte Recruitment and Cytokine Patterns In Vivo

To address the question whether the differences in the lipid A structures could affect the inflammatory response in vivo, we analyzed leukocytes recruitment in the bronchoalveolar lavage fluid (BALF) of C57Bl/6 mice exposed for 16 h to different LPS structures of strains AA2, AA43 and AA44 by means of nasal instillation. While there was no significant difference in monocytes and lymphocytes number (data not shown), neutrophils profile showed striking differences in total differential cell counts (Figure 4A). Significant higher recruitment of neutrophils was observed in mice exposed to LPS from AA2 strain in comparison with those treated with LPSs from AA43 and AA44 (LPS AA2 vs AA43 and AA44 p < 0.001). Cytokines levels were tested in the murine lung homogenates. MIP-2 level in lungs treated with LPS from AA2 strain was significantly higher than those treated with LPSs from AA43 and AA44 strains (LPS AA2 vs AA43 and AA44 p < 0.001) (Figure 4B). Similar trends were obtained with IL-1β and KC (Figure 4C and D).

Murine lung histopathology showed that the LPS from AA2 strain (Figure 5A and B) caused more severe lesions and leukocytes recruitment in the airways than LPSs from AA43 and AA44 strains did (Figure 5C, D, E and F) indicating a reduced detection for LPS isolated in the late P. aeruginosa strains.

Structural Analysis of P. aeruginosa PGN Fragments and Muramyl Peptides in Clonal Strains of Early Colonization and Late Chronic Infection

PGNs from strains AA2, AA43 and AA44 were digested by the muramidase mutanolysin to generate the entire spectrum of muropeptides. The generated PGN fragments were reduced with sodium borohydride, then identified by RP-HPLC and LC-MS (Figure S3 and S4) [17,18]. The composition is reported in Table 1 (see Supporting Information File S1 for the whole structure determination).

Despite the presence of common fragments in the muropeptide blend deriving from the bacterial PGNs, the relative ratio among the peaks sensibly changed among strains AA2, AA43 and AA44 and, furthermore, distinctive chemical features were found in the structure of some minor constituents of the muropeptides mixture (Table 1).

PGN of P. aeruginosa Early Strain Induces Higher Inflammatory Response than Those of Late Strains in Human Cells via Activation of Nod1

HEK293 cells were transfected with hNod1 or hNod2 and stimulated with different concentrations of PGN of AA2, AA43 and AA44.
and AA44 (0.5, 1 and 10 μg/mL) during 18 h. γTriDAP and MDP were used as positive controls. In HEK293hNod1 cells, PGN from AA2 strain induced a major NF-κB activation with respect to PGNs from AA43 and AA44 in a dose dependent manner (PGN AA2 vs AA43 and AA44 p<0.05) (Figure 6A). In contrast with these results no NF-κB activation was found in HEK293 cells expressing hNod2 under the same experimental conditions applied for Nod1 (Figure 6D). IL-8 expression, measured by real time q-PCR in HEK293hNod1 cells treated as above, was significantly higher after stimulation with PGN of AA2 when compared to stimulation with PGNs from AA43 and AA44 (PGN AA2 vs AA43 and AA44 p<0.05) (Figure 6B). IL-8 secretion was measured at 24 h post-transfection. PGN from AA2 strain induced a higher IL-8 production compared to PGNs from AA43 and AA44 strains (PGN AA2 vs AA43 and AA44 p<0.05) (Figure 6C). Transfection of HEK293-hNod1 cell monolayers with a plasmid encoding siRNA for Nod1 prevented the PGNs of the three P. aeruginosa strains to activate NF-κB (Figure 6A and B). Likewise, IL-8 expression and production was abolished in the presence of Nod1 siRNA (Figure 6C). None of PGN tested activated IL-8 expression and secretion in HEK-293hNod2 (Figure 6E and F).

Next, Nod1 and Nod2 expression were confirmed in IB3-1 and C38 cells in the absence or presence of stimuli by real time q-PCR (data not shown). TNF-α and IL-8 expression by real time q-PCR was measured at higher levels in IB3-1 cells treated with PGN from AA2 in comparison to PGNs from AA43 and AA44 (PGN AA2 vs AA43 and AA44 p<0.05) (Figure 7A and B). In agreement with these results, levels of IL-8 proteins of cells stimulated with PGN from AA2 were higher than those elicited by PGNs from AA43 and AA44 (PGN AA2 vs AA43 and AA44 PGN p<0.05) (Figure 7C). Similar results were obtained in C38 cells even though these cells were generally less responsive when compared to IB3-1, as showed above for LPS.

**Discussion**

In this work, we analysed the PAMPs chemical modification as a strategy of P. aeruginosa to hijack genes involved in innate immune responses and to favour survival in patients with CF. A major...
question, derived from previous reports [7,8], was whether \textit{P. aeruginosa} could establish life-long chronic infections in CF hosts according with strategies used by a number of other bacterial pathogens. Persistence is normally established after an acute period of infection involving activation of both the innate and acquired immune system. While the acute infection is usually fully resolved by eliminating the invading bacteria, some bacteria including \textit{Salmonella enterica sv typhi}, \textit{Helicobacter pylori}, \textit{Mycobacterium tuberculosis} and others survive and cause persistent life-long infection by evading immune surveillance [19].

Chemical structure of LPS and PGN were determined for three \textit{P. aeruginosa} clones isolated from airways of a CF patient during a period of 7.5 years. Our previous study showed that these \textit{P. aeruginosa} strains, which were isolated at the late stage of CF chronic infection, have better capacity to persist in the murine lung and to cause chronic infection when compared to early strain [8]. Overall, in all three strains LPS lipid A were consistent with the results reported previously though this molecule displayed much more heterogeneous composition than other case-studies [10,11,20]. Among the three strains LPS lipid A diversity was observed in the number and location of fatty-acid side chains. Early AA2 and late AA43 mucoid \textit{P. aeruginosa} strains synthesized a LPS blend essentially composed by tetra-, penta- and hexa-acylated species lacking 10:0 (3-OH) primary fatty acid. In contrast, the late non-mucoid AA44 strain was constituted by homologue lipid A species which further carried a 10:0 (3-OH) residue, i.e., hexa-acylated and hepta-acylated moieties. These findings are in accordance with previous observations [10,11,20] that \textit{P. aeruginosa} synthesizes more highly acylated (hexa- and hepta-acylated) LPS structures during adaptation to the CF airways. Furthermore, our data might be particularly significant as here we compare LPS of a pair of serial \textit{P. aeruginosa} strains, including mucoid and non-mucoid phenotypes. In mucoid AA43 strain the capsule may act as a physical barrier thus partially preventing invasion by host phagocytes and can also mask the LPS molecules to prevent complement deposition, as observed in other microorganisms, such as \textit{E. coli}, \textit{Haemophilus influenzae} and \textit{Klebsiella pneumoniae} [21,22,23]. By contrast, for the non-mucoid AA44 the absence of capsule may make this strain more susceptible to phagocytosis. This issue could underline a major selective pressure on AA44 to drastically reduce the immunostimulatory activity of its LPS, promote intracellular survival and resistance to antimicrobial peptides through relevant structural changes in lipid A.

As previously described, \textit{P. aeruginosa} strains with severe CF lung disease lacked deacylated lipid A structures, suggesting that loss of deacylation enzymatic activity (PagL) can occur during long-term adaptation to the CF airway [10,24]. Retention of the 3-hydroxydecanoic acid at the lipid A 3-O position is presumably due to lack of expression of PagL, a recently identified 3-O position lipid A deacylase [13]. However, genetic data in support of biological activity have not been provided yet. Here, sequence analysis and alignment of the three clonally related \textit{P. aeruginosa}

---

Figure 4. Neutrophils recruitment and cytokines release in murine lungs after 16 h treatment with LPS derived from clinical \textit{P. aeruginosa} strains. C57Bl/6 mouse were exposed for 16 h to 10 mg/mouse of LPS derived from a \textit{P. aeruginosa} reference strain (PAO1) and three clinical isolates (AA2, AA43 and AA44). A) Total cells were recovered from the BALF and quantified. B, C and D) MIP-2, IL-1β and KC secretions were quantified by ELISA in lung homogenates. *p<0.05, **p<0.01 in the Student’s t-test.

doi:10.1371/journal.pone.0008439.g004
species indicated that the acylation state of lipid A can alter TLR4-mediated responses [25]. In general, production of fully hexa-acylated lipid A is associated with a more strong TLR4 mediated inflammatory response while lipid A with lower levels of acylation triggers reduced cellular responses [25]. This notion has been also demonstrated in *P. aeruginosa* when single species of penta- or hexa-acylated lipid A were tested [11], while in *Salmonella* hepta-acylated isoforms display significantly lower stimulatory activity as compared to the hexa-acylated species [26]. Interestingly, our results suggested that, in addition to the isoforms, also the ratio of penta- and hexa-acylated lipid A had an impact on the biological activity. As shown previously, lipid A under-acylated with respect to hexa-acylated is not only reduced in its ability to stimulate host cellular immune responses, but can also act as antagonist capable of blocking the immunopotential of hexa-acylated *E. coli* LPS lipid A [27,28,29,30,31]. In particular, penta-acylated lipid A of *P. aeruginosa* could antagonize TLR-4 dependent responses of the human cells to hexa-acylated lipid A from *E. coli* [32].

On the basis of the previous notions it was not surprising that in our study LPS of the late AA43, harbouring a mixture of hexa- and under-acylated lipid A, and AA44, presenting hexa-acylated and hepta-acylated lipid A moieties, displayed a reduced immunomodulatory TLR4-mediated activity compared to LPS of early AA2. In particular, the LPSs of AA43 and AA44 showed weak NF-κB and IL-8 inflammatory response when tested in HEK293 cells expressing TLR-4. Similar results were confirmed in macrophage-like THP-1 cells, in a CF airway epithelial IB3-1cell line and in its isogenic non-CF C38 cells, even though the latter were reported as generally less responsive to stimuli when compared to IB3-1 [33]. In the lung of mice neutrophils recruitment was higher after stimulation with lipid A from early AA2 strain with respect to lipid A from late strains AA43 and AA44. A pool of cytokines including MIP-2, KC and IL-1β were found decreased confirming a reduced inflammation for the LPSs of late strains. Altogether these results emphasize the reduced immunopotential of LPS extracted from late colonizer *P. aeruginosa* strains, in line with other reports that demonstrated the lost of large arsenal of virulence factors during chronic infection [7].

We supported the findings described above on LPS by analysing PGN, as additional structure, in our *P. aeruginosa* strains. The concept that bacteria could modulate PGN composition to escape the immune surveillance has been recently reported for pathogens and commensals but not in *P. aeruginosa* [34,35,36,37,38]. In accordance with data of lipid A composition, structural analysis of PGN fragments derived by muramidase digestion of PGN from the three clonal strains of *P. aeruginosa* showed a different relative amount of muropeptides.

Despite these differences and in agreement with the biological impact of lipid A of the three clinical isolates, muropeptides of the late AA43 and AA44 strains displayed a dramatic reduced ability to stimulate the Nod1 receptor in HEK293 and CF cells, with respect to PGN of the early AA2 strain. Nod1 and not Nod2 is involved in the NF-κB and IL-8 mediated response to *P. aeruginosa* PGN, as shown in HEK293 cells expressing alternatively these two PRRs or silenced for Nod1. This result is consistent with another previous study [39] that reported the peculiar ability of *P. aeruginosa* to elicit a Nod1-mediated response. At our knowledge, this is a first report that shows an immune evasion strategy involving the in vivo selection of pathogenic morphotypes harboring PAMP variants able to modulate recognition by different PRRs.

The minimal structure recognized by Nod1 is the dipeptide D-γ-glutamyl-meso-diaminolimelic acid (iEDAP) [40] while it is evident that the intact macromolecular PGN does not stimulate Nod1. It was initially described that the Nod1 recognition system...
requires the exposure of the DAP moiety [40]. Then, other reports, employing synthetic compounds, demonstrated that an exposed DAP moiety is not essential for sensing by Nod1 [41,42]. However, the identity of major Nod1 stimulatory molecule(s), as well as that of putative antagonistic molecules, remains still unknown.

Therefore, as the molecular details of the PGN-Nod1 relationship are not yet elucidated, we are not able to clarify the mechanisms underlining the reduction of Nod1 activation observed with the PGN of the P. aeruginosa strains isolated from the chronic stage of the infection. Difference in muropeptide composition suggests that the enzymatic mechanisms accounting for PGN modifications in AA2, AA43 and AA44 are different or at least differently regulated in these strains. For example, we may observe a reduced amount of GlcNAc2MurNAc(Anh)1MurNAc1Ala4Glu2DAP2 in the PGN of AA44 strain with respect to the other two strains. This might indicate that the activity of the P. aeruginosa lytic transglycosylases already identified on the P. aeruginosa genome [43] is different in AA44 with respect to the other strains. However, we might address the question of how the reduced activation of TLR4 and Nod1 could help the persistence of the P. aeruginosa strains associated to late stage of CF infection. Actually, the reduced production of inflammatory mediators following activation of TLR4 by LPS of late colonizer strains could account for an impaired ability of the host to mount an adequate reaction aimed at P. aeruginosa clearance. Likewise, the role of Nod proteins, and in particular Nod1, has been recently demonstrated in the lung infections sustained by bacterial pathogens, such as Chlamydophila pneumoniae [44,45]. In particular, it has been reported that in a

Table 1. Peptidoglycan composition of P. aeruginosa strain AA2, AA43 and AA44 after mutanolysin hydrolysis.

|      | AA2                  | m/z*   | % compared to total area of peaks | % compared to more abundant peak |
|------|----------------------|--------|-----------------------------------|----------------------------------|
| 1    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 870    | 10.4%                             | 40.9%                            |
| 2    | GlcNAc, MurNAc, Ala, Glu, DAP, Gly1 | 927    | 5.0%                              | 19.7%                            |
| 3    | GlcNAc, MurNAc, Ala, Glu, DAP-Lys1 | 998    | 7.7%                              | 30.2%                            |
| 4    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 942    | 25.6%                             | 100%                             |
| 5    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1722   | 3.7%                              | 14.7%                            |
| 6/7  | GlcNAc, MurNAc, Ala, Glu, DAP, Lys1 | 1922   | 6.9%                              | 26.9%                            |
| 7    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1974   | 4.4%                              | 17.1%                            |
| 8    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1865   | 22.3%                             | 87.1%                            |
| 9    | GlcNAc, MurNAc(Anh), MurNAc, Ala, Glu, DAP2 | 1845   | 13.9%                             | 54.3%                            |

|      | AA43                 | m/z*   | % compared to total area of peaks | % compared to more abundant peak |
|------|----------------------|--------|-----------------------------------|----------------------------------|
| 1    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 870    | 13.3%                             | 42.2%                            |
| 2    | GlcNAc, MurNAc, Ala, Glu, DAP, Gly1 | 927    | 2.4%                              | 7.5%                             |
| 3    | GlcNAc, MurNAc, Ala, Glu, DAP-Lys1 | 998    | 7.5%                              | 23.8%                            |
| 4    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 942    | 31.5%                             | 100%                             |
| 5    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1722   | 1.2%                              | 3.7%                             |
| 6/7  | GlcNAc, MurNAc, Ala, Glu, DAP-Lys1 | 1922   | 5.7%                              | 18.2%                            |
| 7    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1794   | 2.3%                              | 7.2%                             |
| 8    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1865   | 22.0%                             | 69.5%                            |
| 9    | GlcNAc, MurNAc(Anh), MurNAc, Ala, Glu, DAP2 | 1845   | 14.0%                             | 44.4%                            |

|      | AA44                 | m/z*   | % compared to total area of peaks | % compared to more abundant peak |
|------|----------------------|--------|-----------------------------------|----------------------------------|
| 1    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 870    | 16.0%                             | 65.5%                            |
| 2    | GlcNAc, MurNAc, Ala, Glu, DAP, Gly1 | 927    | 5.7%                              | 23.5%                            |
| 3    | GlcNAc, MurNAc, Ala, Glu, DAP-Lys1 | 998    | 7.5%                              | 30.8%                            |
| 4    | GlcNAc, MurNAc, Ala, Glu, DAP1 | 942    | 24.4%                             | 100%                             |
| 5    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1722   | 7.0%                              | 28.7%                            |
| 6    | GlcNAc, MurNAc, Ala, Glu, DAP-Lys1 | 1922   | 1.9%                              | 7.6%                             |
| 7    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1794   | 10.0%                             | 41.1%                            |
| 8    | GlcNAc, MurNAc, Ala, Glu, DAP2 | 1865   | 18.2%                             | 74.6%                            |
| 9    | GlcNAc, MurNAc(Anh), MurNAc, Ala, Glu, DAP2 | 1845   | 9.1%                              | 37.3%                            |

*m/z* mass/charge.
The percentage are based on peak areas derived by HPLC analysis.
doi:10.1371/journal.pone.0008439.t001
murine model of infection the absence of Rip2, which acts as an adaptor molecule in Nod signalling, favors significant delay in \textit{C. pneumoniae} clearance from the lungs and promotes more severe and chronic lung inflammation.

Taken together our results, obtained by comparing sequential strains isolated from one CF patient, showed that the synergy of the action of the two modified \textit{P. aeruginosa} PAMPs, PGN and lipid A, could drastically impair the CF host immune detection system thus preventing the eradication of the infection with this pathogen. This failure occurs despite the deleterious consequence of the persistent inflammatory reaction that leads to the decline of lung function and likely to fatal outcome of the disease. These findings emphasize further studies to determine the generality of this mechanism with additional \textit{P. aeruginosa} clonal lineages or to establish whether other bacterial ligands play a critical role in evading immune system thus promoting survival and establishing favourable conditions for chronic persistence in CF patients.

**Materials and Methods**

**Ethics Statement**

Animal studies were conducted according to protocols approved by the San Raffaele Scientific Institute (Milan, Italy) Institutional Animal Care and Use Committee (IACUC) and adhered strictly to the Italian Ministry of Health guidelines for the use and care of experimental animals.

Research on the bacterial isolates from the individual with CF has been approved by the responsible physician at the CF center at Hannover Medical School, Germany. All patients gave informed consent before the sample collection. Approval for storing of biological materials was obtained by the Hannover Medical School, Germany.

**Bacterial Strains and CF Patient**

\textit{P. aeruginosa} clinical isolate AA2 was obtained from sputa or throat swabs from CF patient homozygous for \textit{DF508} \textit{cftr} mutation attending the Medizinische Hochschule of Hannover, Germany at the onset of chronic colonization. AA43 and AA44 were collected 7.5 years after acquisition and before patient’s death. Two intermediate \textit{P. aeruginosa} strains, AA11 and AA12, were also isolated after one year of infection from this patient [8]. Additional clinical data were reported in the online data supplement (Figure S1). Genotypic and phenotypic data of \textit{P. aeruginosa} strains were published previously [8,46,47]. In particular, to establish the mucoid phenotype quantitative determination of alginate production by \textit{P. aeruginosa} strains was carried out by carbazole assay as already reported elsewhere [46,8]. PAO1 was used as reference strain [48].

\textit{P. aeruginosa} was cultured in \textit{Pseudomonas} isolation agar (PIA) or Trypticase Soy Broth (TSB) at 37°C.

**LPS and PGN Extraction and Lipid A and Muropeptide Identification**

See Supporting Information File S1.

**Sequence Analysis**

One loop of a single \textit{P. aeruginosa} colony, grown on PIA, was processed for DNA extraction using a commercial DNA isolation kit (Qiagen) according to the instructions of the manufacturer. PCR amplifications of the entire \textit{pagL}, \textit{phoP}, \textit{phoQ}, \textit{lpoS1} and \textit{lpoS2} genes were carried out using Taq DNA polymerase (Qiagen). The primers used were detailed in the Online data supplement (Table S1 in Supporting Information File S1). The amplified DNA samples were sequenced by standard automated DNA sequence technology employing the primers described above. The sequence results were
compared with the PAO1 sequence (www.pseudomonas.org) by the BLAST programme at the NCBI database (www.ncbi.nlm.nih.gov/blast/) and within the strains of the AA lineage in order to determine the occurrence of sequence variants.

Cell Cultures and Transfections

The human embryonic Kidney epithelial cell line HEK 293 was grown in D-MEM supplemented with 10% of FBS (both by Cambrex Bio Science). Stably transfected cell line HEK 293-hTLR4/MD2-CD14 (InvivoGen) was cultured in DMEM with 10% FBS and 10 \( \mu \)g/mL Blasticidin-S and 50 \( \mu \)g/mL Hygro-Gold® (both by InvivoGen). HEK293 cells were transiently transfected with PolyFect Transfection Reagent (Qiagen) according to the manufacturer’s instructions. For NF-kB studies, the cells were transfected overnight with a reaction mix composed by 1 \( \mu \)L of PolyFect Transfection Reagent (Qiagen), 150 ng of Firefly luciferase reporter constructs, pGL3.ELAM.tk (containing NF-kB promoter sequences), and 15 ng of Renilla luciferase reporter plasmid, pRLTK (as an internal control).

To study Nod\(_1\) activity, HEK293 cells were transfected with 10 ng of hNod1 (pcDNA3-Nod1-FLAG) or 1 ng hNod2 (pUNO-hNOD2a – InvivoGen). Vector plasmids (pcDNA3) were used as controls in all transfection experiments.

siRNA Assay

siRNA inhibition of Nod1 was carried out as previously described [49] by using psiRNAh-Nod1(InvivoGen). Briefly HEK293 were transfected with 1 ng of plasmid expressing psiRNA or vector control (containing a scramble sequence) together with the plasmid expressing hNod1. Nod1 inhibition was evaluated through western blot analysis with mouse mAbs anti-DYKDDDK (Clone 2EL-1B11, Chemicon International) as previously reported [49].

Cell Cultures of CF Origin

IB3-1 cells, an adeno-associated virus-transformed human bronchial epithelial cell line derived from a CF patient (ΔF508/ W1282X) and C38 cells, the rescued cell line which expresses a plasmid encoding a copy of functional CFTR, have been obtained from LGC Promochem [50,51]. Cells were grown in LHC-8 media (Biosource) supplemented with 5% foetal bovine serum (FBS) (Cambrex Bio Science). All culture flasks

---

**Figure 7. Response of IB3-1 and C38 cells after stimulation with PGN derived from the three clinical isolates of *P. aeruginosa* AA2, AA43 and AA44.**

A) Fold of induction of TNF-\( \alpha \) and (B) IL-8 mRNA after stimulation with 1 \( \mu \)g/mL of PGN for 4 h. The values represent the expression levels relative to untreated IB3-1 (means±SD). C) IL-8 secretion after stimulation with 1 \( \mu \)g/mL of PGN for 24 h. *p<0.05, **p<0.01, ***p<0.001 in the Student’s t-test.

doi:10.1371/journal.pone.0008439.g007
and plates were coated with a solution of LHC-basal medium (Biosource) containing 33 μg/mL bovine collagen (BD Biosciences), 1 μg/mL bovine serum albumin (BSA, Sigma) and 10 μg/mL human fibronectin (BD Bio Science) as described [50].

Cells were seeded at the density of 8 x 10^4 cells/cm² for 4 h experiments and 4 x 10^4 cells/cm² for the 24 h experiments. The day after cells were treated with 100 ng/mL of LPS derived from the clinical isolates AA2, AA43 and AA44. LPS from *P. aeruginosa* serotype OIII:B4 (Sigma) was used as positive controls at the concentration of 10 µg/mL. Growth media were collected at the end of incubation, centrifuged and stored at −80°C, while cells were lysed.

**Culture of a Macrophagic Cell Line**

The non-adherent human myelomonocytic THP-1 cells, obtained from LGC Promochem, were grown in RPMI-1640 supplemented with 10% FBS. Cells were seeded at the density of 8 x 10^4 cells/cm² and allowed to differentiate to macrophage like cells by induction with 60 ng/mL of phorbol myristic acid (PMA) for 36 h, as described previously [52]. The differentiated cells were treated for 6 h with 100 ng/mL of LPS derived from the clinical isolates AA2, AA43 and AA44. LPSs from *P. aeruginosa* serotype OIII:B4 and from *E. coli* serotype OIII:B4 (Sigma) were used as controls. Growth media were collected at the end of incubation, centrifuged and stored at −80°C.

**LPS and PGN Stimulations and NF-κB Activity Assessment**

For LPS, the day before stimulation HEK 293-hTLR4/hMD2-CD14 cells were transiently transfected with the NF-κB reporter constructs as above. Twenty-four hours post-transfection, cells were left untreated or incubated during 4 h with NF-κB and IL-8 mRNA or 24 h (for ELISA) with different concentrations of LPS purified from the clinical isolates AA2, AA43, and AA44. Commercial LPS of *P. aeruginosa* PAO1 (10–50–100 ng/mL) (Sigma) was used as positive controls.

For PGN, HEK 293 cells were simultaneously transfected with (i) hNod1 or hNod2 (ii) NF-κB reporter constructs and (iii) muramidase mutanolysin-digested PGN (Sigma) purified by (A) or (B) from the clinical isolates AA2, AA43, and AA44. NF-κB-dependent luciferase activation and IL-8 mRNA evaluation was measured at 18 h of post-transfection while IL-8 ELISA was performed at 24 h post-transfection.

To measure NF-κB activity, cells stimulated with LPS or PGN, were lysed in 30 µL of passive lysis buffer, and 10 µL of lysate were assayed for Firefly and Renilla activity according to the manufacturer’s instructions. The data shown represent the mean values±S.D. of three separate experiments performed in duplicate. Results are reported as fold induction of relative luciferase units (RLU) over unstimulated cells. Relative luciferase activity is calculated as the ratio between the value of the NF-κB inducible Firefly luciferase and that of the constitutive Renilla luciferase reporter.

**RNA Quantification**

Total RNA was extracted from lysed cells with the Total RNA isolation kit (Roche), converted to cDNA with High Capacity cDNA Archive Kit (Applied Biosystems) and random primers and finally amplified using the Platinum* SYBR® Green qPCR SuperMix-UDG (Invitrogen) as described [53]. Primer sets for TNF-α and IL-8 have been reported previously (Sigma-Genosys) [54,53].

**IL-8 and TNF-α Secretion**

Released IL-8 and TNF-α were determined in supernatants collected from the cell cultures using ELISA kits (Biosource Europe and R&D Systems). According to the manufacturer the sensitivities of the assays are less than 0.7 pg/ml for IL-8 and 11 pg/ml for TNF-α. Measurements were performed at least in duplicate. Values were normalized to 10^6 cells; results were expressed as mean±SD.

**Animals**

C57Bi/6 mice (20–22 gr) were purchased by Charles River. Mice were housed in filtered cages under specific-pathogen conditions and permitted unlimited access to food and water. Mice were exposed to intranasal injection of LPS (10 mg/mouse) derived from *P. aeruginosa* Control animals were exposed to PBS. Animals were housed in filtered cages under specific-pathogen conditions and permitted unlimited access to food and water. Mice were exposed to intranasal injection of LPS (10 mg/mouse) derived from *P. aeruginosa*. Control animals were exposed to PBS. Animals were exposed to intranasal injection of LPS (10 mg/mouse) derived from *P. aeruginosa*. Control animals were exposed to PBS. At six hours after exposure, mice were sacrificed by CO₂, the lungs were removed and homogenized in 1 ml of PBS with 10% Triton X-100.

**Measurement of Murine Cytokines**

IL-1β, KC and IFN-γ concentration in lung homogenates were determined by ELISA (R&D Systems), according to manufacturer instructions using antibody pairs and recombinant standards from R&D System.

**Histology**

For histopathology, lungs were removed en bloc and fixed in 4% paraformaldehyde/PBS, at 4°C for 24 h, and processed for paraffin embedding. Longitudinal sections of 5 µm thick were obtained using a microtome from the proximal, medial and distal lung regions. Sections were stained with H&E according to standard procedures.

**Statistical Analysis**

Statistical calculations and tests were performed using Student’s *t* test considering p≤0.05 as limit of statistical significance. All data were expressed as mean±standard deviation (SD).

**Supporting Information**

**Figure S1** *P. aeruginosa* sequential isolates from patient AA. Found at: doi:10.1371/journal.pone.0008439.s001 (0.16 MB TIF)

**Figure S2** Sequence alignment of pagL in sequential *P. aeruginosa* isolates. Found at: doi:10.1371/journal.pone.0008439.s002 (0.93 MB TIF)

**Figure S3** RP-HPLC analysis of PGNs fragments. Found at: doi:10.1371/journal.pone.0008439.s003 (0.43 MB TIF)
Acknowledgments

The authors thank B. Tummler, Klinische Forschergruppe, OE 6710, Medizinische Hochschule Hannover, Hannover, Germany, for supplying the P. aeruginosa strains from CF patients.

Author Contributions

Conceived and designed the experiments: AM MLB AB. Performed the experiments: CC LC MRL TI NIB IB. Analyzed the data: CC LC MRL TI NIB IB AS FC RL. Contributed reagents/materials/analysis tools: AS FC RL AM MLB AB. Wrote the paper: AM MLB AB.

References

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783–801.
2. Pross M, Riedl SJ, Fritz JH, Rejas AM, Schwarzenberger R (2008) The Nod-Like Receptor (NLR) Family: A Tale of Similarities and Differences. PLoS ONE 3: e219.
3. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, et al. (2003) Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300: 1594–1597.
4. Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, et al. (2003) Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 278: 41702–41709.
5. Finlay BB, McDade G (2006) Anti-immunomodulation: evasion of the host immune system by bacterial and viral pathogens. Cell 124: 767–782.
6. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918–931.
7. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 30: 8477–8482.
8. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, et al. (2009) Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. J Allergy Clin Immunol 124: 767–774.
9. Sadikot RT, Blackwell TS, Christman JW, Prince AS (2005) Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171: 1209–1223.
10. Ernst RK, Moskowitz SM, Ersenser JG, Kraig GM, Adams KN, et al. (2007) Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis 196: 1086–1092.
11. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI (2002) Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 3: 354–359.
12. Kawasaki K, Ernst RK, Miller SI (2004) 3-O-deacylation of lipid A by PagL, a lipoprotein of Pseudomonas aeruginosa. J Endotoxin Res 12: 324–336.
13. Miller SI, Ernst RK, Bader MW (2005) LPS, TLR4 and infectious disease. ASM Chemother 31: 178–182.
14. Kawasaki K, Ernst RK, Miller SI (2004) 3-O-deacylation of lipid A by PagL, a lipoprotein of Pseudomonas aeruginosa. J Endotoxin Res 12: 324–336.
15. Chen G, Shaw MH, Kim YG, Nunez G (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4: 365–398.
16. Knirel YA, Bystrova OV, Kocharova NA, Zähringer U, Pier GB (2006) Peptidoglycan cell wall fragments of Pseudomonas aeruginosa: Novel structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes and Infection 5: 1057–1063.
17. Glauner B (1988) Separation and quantification of muropeptides with high-performance liquid chromatography. Anal Biochem 172: 451–464.
18. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jejanno M, et al. (2003) Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes and Infection 5: 1057–1063.
19. Boneca IG, Dussurget O, Cabanes D, Nahori MA, Sousa S, et al. (2005) A family of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Cell Microbiol 7: 675–686.
20. Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J Biol Chem 284: 5574–5585.
21. Miller SI, Ernst RK, Bader MW (2005) LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 3: 36–46.
22. Cao Y, Zhao MH, Kim YG, Nunez G (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4: 395–398.
23. Giannelli D, Massari L, Provasoli D, Conti A, Lanzoni S, et al. (2006) Conserved and variable structural features in the lipopolysaccharide of Pseudomonas aeruginosa. J Endotoxin Res 12: 324–336.
24. Glauner B (1988) Separation and quantification of muropeptides with high-performance liquid chromatography. Anal Biochem 172: 451–464.
25. Garcia-Bustos JF, Douglas J, Iyengar S, Canning J, Hwang J, et al. (2008) Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes and Infection 5: 1057–1063.
26. Boneca IG, Dussurget O, Cabanes D, Nahori MA, Sousa S, et al. (2005) A family of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Cell Microbiol 7: 675–686.
46. Bragonzi A, Wiehlmann L, Klockgether J, Cramer N, Wollitzsch D, et al. (2006) Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 152: 3261–3269.

47. Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, et al. (2007) Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153: 1445–1454.

48. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, et al. (2000) Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406: 959–964.

49. Nigro G, Fazio LL, Martino MC, Rossi G, Tattoli I, et al. (2008) Muramylpeptide shedding modulates cell sensing of Shigella flexneri. Cell Microbiol 10: 682–695.

50. Zeitlin PL, Lai L, Rhim J, Cutting G, Stetten G, et al. (1991) A cystic fibrosis bronchial epithelial cell line: immortalization by adenovirus-12-SV40 infection. Am J Respir Cell Mol Biol 4: 313–319.

51. Egan M, Flotte T, Afione S, Sokol R, Zeitlin PL, et al. (1992) Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR. Nature 358: 581–584.

52. Verma N, Chaudhury I, Kumar D, Das RH (2009) Silencing of TNF-α receptors co-ordinately suppresses TNF-α expression through NF-κB activation blockade in THP-1 macrophage. FEBS Letters 583: 2968–2974.

53. Cigana C, Assael BM, Melotti P (2007) Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51: 973–981.

54. Cigana C, Nicolò E, Pasero M, Assael BM, Melotti P (2006) Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 350: 977–982.